Trypanosomiasis

Summary

Trypanosomiasis (MONDO:0000940) is a disease and 2 clinical trials. Top therapeutic interventions include benznidazole and acoziborole. A subtype of protozoa infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	trypanosomiasis
Mondo ID	MONDO:0000940
MeSH	D014352
DOID	DOID:10113
ICD-10-CM	B56
SNOMED CT	78940002
UMLS	C0041227
MedGen	52872
Is cancer (heuristic)	no

Also known as: Trypanosoma caused disease or disorder · Trypanosoma disease or disorder · Trypanosoma infectious disease · Trypanosomiases

Disease family

This is a subtype of protozoa infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › parasitic infectious disease › protozoa infectious disease › trypanosomiasis

Related subtypes (14): primary amebic meningoencephalitis, granulomatous amebic encephalitis, giardiasis, protozoal dysentery, trichomoniasis, malaria, Acanthamoeba keratitis, amebiasis, babesiosis, balantidiasis, coccidiosis, theileriasis, leishmaniasis, dientamoebiasis

Subtypes (2): Chagas disease, human African trypanosomiasis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

Drugs indicated for this disease

6 approved, 3 in late-stage (phase 3) trials. Disease-direct ChEMBL indications, not inferred from the associated-gene cohort below.

Drug	Development status
Acetarsone	Approved (phase 4)
Benznidazole	Approved (phase 4)
Fexinidazole	Approved (phase 4)
Miltefosine	Approved (phase 4)
Nifurtimox	Approved (phase 4)
Nitrofurazone	Approved (phase 4)
Eflornithine	Phase 3 (in late-stage trials)
Meglumine Antimonate	Phase 3 (in late-stage trials)
Melarsoprol	Phase 3 (in late-stage trials)

Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pentamidine.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE3	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00123916	PHASE3	COMPLETED	BENEFIT: Evaluation of the Use of Antiparasital Drug (Benznidazole) in the Treatment of Chronic Chagas’ Disease
NCT01533961	PHASE1	COMPLETED	Human African Trypanosomiasis: First in Man Clinical Trial of a New Medicinal Product, the SCYX-7158

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BENZNIDAZOLE	4	1
ACOZIBOROLE	2	1